Fintech PR
Tigermed Reports 2023 Interim Results
HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ — Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed” or the “company”) (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its interim results for the first half of 2023, ended June 30, 2023 (the “Reporting Period”).
|
This press release is for information and summary only and is not intended to provide any representation, in whole or in part, of the relevant matters. For further information, please refer to the 2023 interim results and relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk). |
|
All financials disclosed in this press release are prepared based on International Financial Reporting Standards (IFRS) except for those specifically noted otherwise. The 2023 Interim Results of the company has not been audited. |
First Half 2023 Financial Performance
- Total revenue achieved 3.2% year-over-year (“YoY”) growth to RMB 3,710.9 million during the Reporting Period.
- Adjusted Net Profit Attributable to the Owners of the Company(1) increased by 2.2 % YoY to RMB 895.6 million during the Reporting Period（1）.
- Segment revenue generated from Clinical Trial Solutions decreased by 3.2% YoY to RMB 2,103.4 million.
- Segment revenue generated from Clinical-related and Lab Services achieved 13% YoY growth and reached RMB 1,607.5 million.
- Geographically, China’s revenue increased by 24.2% YoY to RMB 2,087.4 million. The company’s overseas revenue decreased by 15.2% YoY to RMB 1,623.5 million during the Reporting Period.
|
（1）Non-IFRS measure. Adjusted for (i) share-based compensation expense, (ii) net foreign exchange loss/(gain), (iii) amortization of intangible assets arising from acquisitions, and (iv) changes in fair value of financial assets at FVTPL |
Business Highlight:
Tigermed maintained its strong position in the CRO industry in the first half of 2023 by providing comprehensive services and empowering global biopharmaceutical innovation with high quality and commitment. As of June 30, 2023, Tigermed had 772 ongoing drug clinical research projects, including over 40 ongoing clinical trials in the United States, 35 ongoing clinical trial projects in the EMEA (Europe, Middle East, Africa) region, and 31 ongoing clinical trial projects in South East Asia and Latin America regions.
During the reporting period, Tigermed regulatory affairs (RA) business had 940 accumulated project experience, added 18 new U.S. FDA IND projects, and assisted 7 products to be registered and approved in China. Furthermore, the Tigermed medical device team has served over 1,700 global clients with 5,700+ accumulated medical device and IVD registration projects, as well as 700+ clinical trial experiences.
Tigermed has achieved impressive growth in pharmacovigilance, medical translation, and real-world studies services in the first half of 2023. Notably, pharmacovigilance services added 75 newly signed projects and 59 new customers, providing safety monitoring solutions to both pre-NDA and post-market projects in both Europe and China. Medical translation added 52 new customers while expanding into the Japanese market in 2023. Real-World Study (RWS) business has reached multiple collaborations with global pharmaceutical companies. In terms of vaccine clinical service, Tigermed team has conducted 14 overseas COVID-19 vaccine projects and supported multiple innovative vaccines to carry out phase III protective efficacy research.
As of June 30, 2023, data management and statistical analysis had 296 customers and 859 ongoing projects. Additionally, Tigermed had 1,776 ongoing site management projects and provided services for 11 Class I innovative drug approvals in China in the first half of 2023. Furthermore, Tigermed Excellence for Clinical Trial Sites (“E-Site”) Program had 204 core collaborative sites and 61 green channel sites across China, forming a diversified and win-win strategic cooperation model.
Tigermed laboratory service has achieved great progress as of June 30, 2023. The Frontage Suzhou Safety Assessment Center obtained the GLP (Good Laboratory Practice) certification issued by the NMPA; the new 8,000+ square meters clinical trial manufacture center in Suzhou was officially put into operation; and ACME Biopharma, a subsidiary of Frontage, launched its Wuhan R&D center, offering comprehensive R&D services from target screening to pre-clinical pharmacology research.
During the reporting period, Tigermed DCTs (Decentralized Clinical Trials) Solutions were put into use across several therapeutic areas, such as oncology, Alzheimer’s disease, migraine, diabetes, COVID-19, etc., creating functions including remote follow-up, remote monitoring, remote informing, electronic patient report, etc. Furthermore, the company compiled The Tigermed DCT Global Regulatory Handbook, which became a regulatory reference and guide for DCT applications in global clinical research.
In the first half of 2023, Tigermed achieved a major milestone in its globalization efforts by establishing its International Headquarters in Hong Kong, which will enable the company to coordinate and manage global projects more efficiently and empower customers on a global scale.
As of June 30, 2023, Tigermed total number of employees reached 9,455, of which 1,525 were based overseas. During the reporting period, Tigermed had cumulative experience handling 120+ MRCT projects and 62 ongoing MRCTs. In addition, Tigermed acquired Marti Farm to further strengthen its ability to provide high-quality clinical services in Europe for global customers.
Tigermed has earned recognition from customers, industry, and media across the globe. During the reporting period, Tigermed has been honored with awards such as “Microsoft Digital Platform Best Practices Awards”, “Best Employer Brand on LinkedIn”, and “Best Medical Device Overseas Enabling Service Provider of 2023. Moreover, CSA Research ranked its medical translation business 51st globally (5th in mainland China and 14th in the Asia Pacific) according to the 2023 CSA Research Largest Language Service Providers Ranking.
Management Comment
“At Tigermed, we have taken the initiative to embrace the opportunities and challenges of the CRO industry in the first half of 2023,” said Ms. Xiaochun Cao, Co-Founder, Executive Director, and President of Tigermed. “We focus on globalization, digitalization, and integration as our driving strategies for corporate development, and our comprehensive and reliable clinical research services have helped us build our global reputation. We are consistently striving to enhance service capabilities and scaling our global reach while remaining committed to offering our clients a professional and reliable experience that will ultimately benefit healthcare worldwide.”
Forward-Looking Statements
The information communicated herein may contain certain “forward-looking statements”, which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.
Non-IFRS Measure
To supplement our financial information which are presented in accordance with IFRS, we use adjusted net profit attributable to owners of the Company as an additional financial measure, which is not required by, or presented in accordance with IFRS. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company before certain expenses and amortization. We define adjusted net profit attributable to owners of the Company as profit attributable to owners of the Company adjusted for (1) share-based compensation expense, (2) net foreign exchange loss/(gain), (3) amortization of intangible assets arising from acquisitions, (4) listing expenses incurred by our Group, and (5) increase in fair value of financial assets at FVTPL. Adjusted net profit attributable to owners of the Company is not an alternative to (i) profit before tax, profit for the year or profit for the year attributable to owners of the Company (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity. We believe that this non-IFRS measure is useful for understanding and assessing underlying business performance and operating trends, and that the owners of the company and we may benefit from referring to this non-IFRS measure in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of this non-IFRS measure is not intended to, and should not, be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS measure on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results or a similarly titled financial measure reported or forecasted by other companies.
About Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively. Tigermed Group currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
View original content:https://www.prnewswire.co.uk/news-releases/tigermed-reports-2023-interim-results-301910020.html
BETHESDA, Md., Jan. 10, 2025 /PRNewswire/ — SAR, a data analytics company specialized in the securities litigation risk of U.S. public companies, today published the Securities Class Action Rule 10b-5 Exposure Report for 4Q 2024. According to the report, securities litigation exposure of public company defendants that trade in the NYSE and NASDAQ peaked during the fourth quarter of 2024, when records were set across the buoyant U.S. equity markets. During the bullish market conditions of 2024, shareholders claimed approx. $665.2 billion in market capitalization losses due to alleged violations of Rule 10b-5 – the most in the last five years.
According to the report, global quarterly Rule 10b-5 securities litigation exposure in 2024 was 17% greater than the average of 2023. Actual monetary settlements with investor plaintiffs last year were, on average, 23% greater than during the last six years.
SAR data and analysis indicate that the litigation exposure of U.S. public company defendants amounts to approximately $380.3 billion in 2H 2024. Shareholders claimed approximately $4.0 billion in market capitalization losses per securities class action filing, and approximately $2.0 billion per allegedly fraud-related stock drop in 2H 2024. The former metric increased by 32.1%, and the latter by 15.4% during the second half of 2024.
“Our data and analyses indicate that securities litigation exposure against U.S. public companies peaked in the fourth quarter of last year. This peak may be short-lived with an expected increase in volatility and new headwinds for U.S. equities given greater shareholder scrutiny of corporate disclosures. With average Rule 10b-5 settlements over 20% greater in 2024 than during the last six years, litigation activity is expected to increase in 2025,” said Anthony Kabanek, EVP of SAR.
According to the report, in 2023 and 2024 investor plaintiffs claimed $13.6 billion and $20.5 billion, respectively, in private Rule 10b-5 securities-fraud class actions that relied on short-seller research.
Key takeaways:
- 86 U.S. issuers were sued for alleged violations of Rule 10b-5 during 2H 2024. Based on allegations presented in the first-filed class action complaint against each defendant issuer, U.S. SCA Rule 10b-5 Exposure amounts to $259.4 billion. U.S. SCA Rule 10b-5 Exposure decreased -5.4% relative to 1H 2024.
- U.S. SCA Rule 10b-5 Exposure peaked in the 2nd and 3rd quarters, followed by a decline to trend in the 4th quarter of 2024.
- 9 Non-U.S. issuers were sued for alleged violations of Rule 10b-5 during 2H 2024. Based on allegations presented in the first-filed class action complaint against each defendant issuer, ADR SCA Rule 10b-5 Exposure amounts to $120.9 billion. ADR SCA Rule 10b-5 Exposure increased by 11.3x relative to 1H 2024.
- An anomalously high 4th quarter exposure among Non-U.S. issuers contributed to a remarkably volatile year for ADR SCA Rule 10b-5 Exposure.
- Rule 10b-5 private securities-fraud filing frequency and potential loss severity need not move in tandem. Global exposure increased by approximately 34% in the 2H 2024 relative to 1H 2024, while filing frequency remained relatively stable.
- 38 U.S. Large Caps were sued for alleged violations of Rule 10b-5 in 2H 2024, the same observed frequency as 1H 2024. The U.S. Large Cap SCA Rule 10b-5 Exposure amounts to $233.7 billion, a decrease of 10.1% relative to 1H 2024.
- 22 U.S. Mid Caps were sued for alleged violations of Rule 10b-5 In 2H 2024. The U.S. Mid Cap SCA Rule 10b-5 Exposure amounts to $19.8 billion, more than 3 times the amount in 1H 2024.
- 26 U.S. Small Caps were sued for alleged violations of Rule 10b-5. The U.S. Small Cap SCA Rule 10b-5 Exposure amounts to $5.9 billion, a decrease of 33% relative to 1H 2024.
- 9 Non-U.S. issuers that trade via ADRs in the U.S. public markets were sued for alleged violations of Rule 10b-5. The ADR SCA Rule 10b-5 Exposure increased by over 11.3x to ~$121 billion, relative to 1H 2024.
Media contact: [email protected]
Logo – https://mma.prnewswire.com/media/944961/SAR_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24-302348191.html
STOCKHOLM, Jan. 10, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant exchange rate (CER) (1). Adjusted EBITA margin (1,2) was in the mid-30s per cent of revenues.
The main reasons for the increased revenue are higher sales than expected in Q4 across the Haemophilia portfolio and for Kineret.
- Altuvoct: Higher than expected rate of new patients switching to Altuvoct in markets where the product has been launched, mainly Germany and Switzerland.
- Elocta: Benefited from higher patient numbers across markets and in markets where Altuvoct is launched there were less switches than expected from Elocta. Favorable gross-to-net effects were also observed.
- Alprolix: Higher than expected number of new patients as well as increase in on-demand treatments across Europe.
- Kineret: Higher than expected sales driven mainly by positive gross-to-net adjustments and favorable order phasing but also supported by increased demand.
- The adjusted EBITA margin remained in the expected range as the stronger revenue performance was offset by negative mix effects on the gross margin as well as investments into our launch and pipeline products in the fourth quarter.
At the publication of the Q3 2024 report on 24 October 2024 Sobi stated the outlook for the full year 2024 to be: Revenue was anticipated to grow by a mid-teens percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue.
Sobi will announce its fourth quarter and full year 2024 report on Wednesday 5 February 2025 at 8:00 am CET.
About Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 18:00 CET on 10 January 2025.
Gerard Tobin
Head of Investor Relations
[1] Alternative Performance Measures (APMs).
[2] Excluding items affecting comparability (IAC).
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Sobi’s full year 2024 revenue higher than previous estimate |
View original content:https://www.prnewswire.co.uk/news-releases/sobis-full-year-2024-revenue-higher-than-previous-estimate-302348202.html
Fintech PR
Knowledge Graph Market worth $6,938.4 million by 2030 – Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The Knowledge Graph Market is expected to reach USD 6,938.4 million by 2030 from USD 1,068.4 million in 2024, at a Compound Annual Growth Rate (CAGR) of 36.6% from 2024–2030, according to new research report by MarketsandMarkets™.
The knowledge graphs ensure enterprise knowledge management through the rebuilding of complex data with interconnected nodes and relationships by providing a simpler way to navigate and retrieve information. It helps businesses build a fully comprehensive knowledge graph uniting disparate data sources, enables complex semantic search, context-aware recommendations, and data discovery. Knowledge graphs support better decision-making, foster innovation, and improve cooperation across teams by mapping relationships between organizational knowledge. They are particularly useful for large organizations, which depend on accessing and utilizing vast amounts of structured and unstructured data to be productive and competitive.
Browse in-depth TOC on “Knowledge Graph Market “
344 – Tables
51 – Figures
359 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217920811
Scope of the Report
|
Report Metrics |
Details |
|
Market size available for years |
2019–2030 |
|
Base year considered |
2024 |
|
Forecast period |
2024–2030 |
|
Forecast units |
Value (USD Million) |
|
Segments Covered |
(solutions (enterprise knowledge graph platform, graph database engine, knowledge management toolset) services ( professional services, managed services) by model type (Resource Description Framework (RDF) Triple Stores, Labeled Property Graph (LPG)) by applications (data governance and master data management, data analytics and business intelligence, knowledge and content management , virtual assistants, self-service data and digital asset discovery, product and configuration management, infrastructure and asset management, process optimization and resource management, risk management, compliance, regulatory reporting, market and customer intelligence, sales optimization, other applications) by vertical (Banking, Financial Services, and Insurance (BFSI), retail and eCommerce, healthcare, life sciences, and pharmaceuticals telecom and technology, government, manufacturing and automotive, media & entertainment, energy, utilities and infrastructure, travel and hospitality, transportation and logistics, other vertical) |
|
Region covered |
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America |
|
Companies covered |
IBM Corporation (US), Oracle (US), Microsoft Corporation (US), AWS (US), Neo4j (US), Progress Software (US), TigerGraph (US), Stardog (US), Franz Inc (US), Ontotext (Bulgaria), Openlink Software (US), Graphwise (US), Altair (US), Bitnine ( South Korea) ArangoDB (US), Fluree (US), Memgraph (UK), GraphBase (Australia), Metaphacts (Germany), Relational AI (US), Wisecube (US), Smabbler (Poland), Onlim (Austria), Graphaware (UK), Diffbot (US), Eccenca (Germany), Conversight (US), , Semantic Web Company (Austria), ESRI (US) |
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=217920811
By vertical, the BFSI segment to hold the largest market size during the forecast period.
The knowledge graphs serve as a strong foundation for relating customer data, transactions history, credit scores, and risk profiles within the BFSI (Banking, Financial Services, and Insurance) sector, allowing the exact relationship mapping and insights. These are also employed in fraud detection through real-time identification of hidden patterns and for regulatory compliance with standards such as AML (Anti Money Laundering) and KYC (know Your Customer), where data can be traced and is transparent. In banking, knowledge graphs facilitate credit risk analysis which makes the process of loan approval more efficient, in insurance by linking policies, claims data, and fraud indicators thus optimizing claims processing. All these will, when combined with other data points, produce AI-powered applications: personalized advice-based solutions on finances and intelligent virtual assistants, which will create operational efficiency and improved customer experience in BFSI.
Virtual assistants, self-service data, and digital asset discovery segment to have the highest growth during the forecast period.
Knowledge graphs are essential for building virtual assistants, self-service data platforms, and even digital asset discovery, for they build interconnected data networks that help in enhancing the searchability and insights. Virtual assistants use knowledge graphs to provide context-sensitive responses that improve user interactions and provide tailored recommendations. Self-service data platforms use knowledge graphs to allow business users to access and analyze complex datasets without technical help, which helps them to make better decisions. They make the identification and classification of digital resources, such as documents or media, easier through linking metadata and content relationships for the discovery of digital assets. This capability enables effective resource management, innovation, and improvement in user experience in areas such as content creation, research, and enterprise workflows.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=217920811
Asia Pacific is expected to witness the highest market growth rate during the forecast period.
The knowledge graph landscape is rapidly evolving in Asia Pacific, with initiatives across various domains. In December 2022, the National Library Board (NLB), Singapore, launched a Linked Data-based Semantic Knowledge Graph to merge resources from libraries and archives using BIBFRAME and Schema.org vocabularies for seamless updating and improved data quality. HydroKG in Australia merges hydrologic data from resources such as GeoFabric and HydroATLAS that allow for pinpoint queries on water bodies and river networks, enabling better environmental management. Japan uses knowledge graphs in manufacturing for supply chain optimization and South Korea uses it in telecommunications to enhance the customer experience through personalized AI.
Top Key Companies in Knowledge Graph Market
The major vendors covered in the Knowledge graph market are IBM Corporation (US), Oracle (US), Microsoft Corporation (US), AWS (US), Neo4j (US), Progress Software (US), TigerGraph (US), Stardog (US), Franz Inc (US), Ontotext (Bulgaria), Openlink Software (US), Graphwise (US), Altair (US), Bitnine ( South Korea) ArangoDB (US), Fluree (US), Memgraph UK), GraphBase (Australia), Metaphacts (Germany), Relational AI (US), Wisecube (US), Smabbler (Poland), Onlim (Austria), Graphaware (UK), Diffbot (US), Eccenca (Germany), Conversight (US), Semantic Web Company (Austria), ESRI (US), Datavid (UK), and SAP (Germany). These players have adopted various growth strategies, such as partnerships, agreements and collaborations, new product launches, enhancements, and acquisitions to expand their footprint in the Knowledge graph market.
Browse Adjacent Markets: Information and Communications Technology Market Research Reports & Consulting
Related Reports:
Digital Signature Market – Global Forecast to 2030
AI In Media Market – Global Forecast to 2030
Data Diode Market – Global Forecast to 2030
Geospatial Analytics Market – Global Forecast to 2029
Property Management Market – Global Forecast to 2030
Get access to the latest updates on Knowledge Graph Companies and Knowledge Graph Industry
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/knowledge-graph-market-worth-6-938-4-million-by-2030–exclusive-report-by-marketsandmarkets-302347820.html
-
Fintech5 days agoAsian Financial Forum held next week as the region’s first major international financial assembly of 2025
-
Fintech PR5 days agoOWIT Global Provides Alternative Delivery Models that Adapt to the Continuously Evolving Data Security Demands of the Industry
-
Fintech PR6 days agoHyundai Motor Group Executive Chair Euisun Chung Outlines 2025 Vision Driven by Commitment to Innovation, Overcoming Challenges, and Creating Opportunities in New Year’s Message
-
Fintech PR2 days agoHTX 2025 Outlook: Five Sectors to Look Forward to, and How Trump’s Policy Will Affect Crypto Industry
-
Fintech PR6 days agoZoomlion Accelerates Global Expansion with Localized Innovations in Saudi Arabia
-
Fintech PR2 days agoAZZURRI GROUP LAUNCHES ITS 2024 SUSTAINABLE DINING REPORT AND ACHIEVES FURTHER REDCUTIONS IN CARBON EMISSIONS
-
Fintech PR2 days agoNovo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD
-
Fintech PR2 days agoFintech nsave launches investment platform, offering people from distressed economies protection from inflation with compliant and safe investments abroad